Stifel Nicolaus Provides Cautious Outlook for Bolt Biotherapeutics (NASDAQ:BOLT) Stock

On March 27, 2025, Stifel Nicolaus, a respected equity research firm, lowered its price target for Bolt Biotherapeutics (NASDAQ:BOLT) from $1.50 to $1.25. This adjustment was made in a report highlighting their current stance on the stock, where they now hold a "hold" rating. The new price target indicates a potential upside of approximately 184.09% from Bolt Biotherapeutics’ last trading price.

Current Stock Overview

As of Tuesday, shares of NASDAQ:BOLT opened at $0.44. The company's financial ratios display a debt-to-equity ratio of 0.21, a current ratio of 3.16, and a quick ratio of 3.16. The stock's fifty-day moving average stands at $0.47, while its two-hundred-day moving average is $0.56. The company's shares have traded within a range over the past year, hitting a low of $0.38 and a high of $1.56. Currently, Bolt Biotherapeutics has a market capitalization of $16.84 million, a price-to-earnings ratio of -0.26, and a beta of 0.94, indicating less volatility compared to the overall market.

Latest Earnings Results

Bolt Biotherapeutics released its latest earnings report on March 24, 2025. The company reported earnings per share (EPS) of ($0.38), which was in line with analyst expectations. The firm recorded a net margin of -665.56% and a return on equity of -69.46%. Revenue for the quarter amounted to only $0.01 million, significantly lower than the anticipated $0.79 million. Analysts are forecasting that Bolt Biotherapeutics will post an EPS of -1.61 for the current fiscal year.

Institutional Investor Activity

Recently, there has been notable activity among institutional investors concerning Bolt Biotherapeutics. Several firms made moves to adjust their holdings during the fourth quarter. Millennium Management LLC acquired a new stake worth approximately $25,000, while Squarepoint Ops LLC invested around $26,000. Likewise, Velan Capital Investment Management LP purchased shares valued at $27,000, and Citadel Advisors LLC acquired a stake worth $42,000. Additionally, FMR LLC increased its holdings by 33.2%, owning 115,386 shares after adding 28,773 shares over the last quarter. Currently, institutional investors hold about 86.70% of Bolt Biotherapeutics’ stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing immunotherapies for cancer treatment. The company's leading product candidate, BDC-1001, is in clinical development targeting patients with human epidermal growth factor receptor 2-positive solid tumors, which include various forms of cancer such as breast, colorectal, endometrial, and gastroesophageal cancer.

forecast, stocks, finance